[
  {
    "ts": null,
    "headline": "Charles River Laboratories International, Inc. (CRL) Q2 2025 Earnings Call Transcript",
    "summary": "Charles River Laboratories International, Inc. (NYSE:CRL) Q2 2025 Earnings Conference Call August 6, 2025 9:00 AM ETCompany ParticipantsFlavia H.",
    "url": "https://finnhub.io/api/news?id=5759629b39fe2cf6d837275559a2b3150132e6891507bc98429416da8b661a13",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754487047,
      "headline": "Charles River Laboratories International, Inc. (CRL) Q2 2025 Earnings Call Transcript",
      "id": 136238826,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "CRL",
      "source": "SeekingAlpha",
      "summary": "Charles River Laboratories International, Inc. (NYSE:CRL) Q2 2025 Earnings Conference Call August 6, 2025 9:00 AM ETCompany ParticipantsFlavia H.",
      "url": "https://finnhub.io/api/news?id=5759629b39fe2cf6d837275559a2b3150132e6891507bc98429416da8b661a13"
    }
  },
  {
    "ts": null,
    "headline": "Charles River (CRL) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates",
    "summary": "Although the revenue and EPS for Charles River (CRL) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.",
    "url": "https://finnhub.io/api/news?id=c6a04e0ee4a428eb2be9840452dd4b5d5bf575f72fe5b77c8627138cd48984b6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754487008,
      "headline": "Charles River (CRL) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates",
      "id": 136237607,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CRL",
      "source": "Yahoo",
      "summary": "Although the revenue and EPS for Charles River (CRL) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.",
      "url": "https://finnhub.io/api/news?id=c6a04e0ee4a428eb2be9840452dd4b5d5bf575f72fe5b77c8627138cd48984b6"
    }
  },
  {
    "ts": null,
    "headline": "CRL Stock Gains on Q2 Earnings and Revenue Beat, Raises '25 View",
    "summary": "Charles River shares jump 9.3% pre-market after Q2 earnings and revenues beat estimates. The company raises its 2025 outlook.",
    "url": "https://finnhub.io/api/news?id=b4409c4a7afb9624671795188dc21c6e238e3f8ed9725be14ba36b65f984f1da",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754486640,
      "headline": "CRL Stock Gains on Q2 Earnings and Revenue Beat, Raises '25 View",
      "id": 136237333,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CRL",
      "source": "Yahoo",
      "summary": "Charles River shares jump 9.3% pre-market after Q2 earnings and revenues beat estimates. The company raises its 2025 outlook.",
      "url": "https://finnhub.io/api/news?id=b4409c4a7afb9624671795188dc21c6e238e3f8ed9725be14ba36b65f984f1da"
    }
  },
  {
    "ts": null,
    "headline": "Charles River Laboratories (NYSE:CRL) Delivers Impressive Q2",
    "summary": "Lab services company Charles River Laboratories (NYSE:CRL) reported Q2 CY2025 results beating Wall Street’s revenue expectations, but sales were flat year on year at $1.03 billion. Its non-GAAP profit of $3.12 per share was 24.6% above analysts’ consensus estimates.",
    "url": "https://finnhub.io/api/news?id=b99a0836a71e6529fd296c11194e4e2541dc3b7031bd9bc1ffd68548b8fa99c9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754485008,
      "headline": "Charles River Laboratories (NYSE:CRL) Delivers Impressive Q2",
      "id": 136237609,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CRL",
      "source": "Yahoo",
      "summary": "Lab services company Charles River Laboratories (NYSE:CRL) reported Q2 CY2025 results beating Wall Street’s revenue expectations, but sales were flat year on year at $1.03 billion. Its non-GAAP profit of $3.12 per share was 24.6% above analysts’ consensus estimates.",
      "url": "https://finnhub.io/api/news?id=b99a0836a71e6529fd296c11194e4e2541dc3b7031bd9bc1ffd68548b8fa99c9"
    }
  },
  {
    "ts": null,
    "headline": "Charles River: Margin Fears Outweigh Solid Q2",
    "summary": "Charles River Laboratories posted a strong Q2 beat, but results were boosted by one-time items and cost cuts that may not be sustainable.",
    "url": "https://finnhub.io/api/news?id=a4a3990ca881ffddda77564bb0e6824e0de6578adf0389583e20f6beb366735b",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754484450,
      "headline": "Charles River: Margin Fears Outweigh Solid Q2",
      "id": 136238594,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1363326109/image_1363326109.jpg?io=getty-c-w1536",
      "related": "CRL",
      "source": "SeekingAlpha",
      "summary": "Charles River Laboratories posted a strong Q2 beat, but results were boosted by one-time items and cost cuts that may not be sustainable.",
      "url": "https://finnhub.io/api/news?id=a4a3990ca881ffddda77564bb0e6824e0de6578adf0389583e20f6beb366735b"
    }
  },
  {
    "ts": null,
    "headline": "Charles River Laboratories (CRL) Q2 Earnings and Revenues Surpass Estimates",
    "summary": "Charles River (CRL) delivered earnings and revenue surprises of +24.80% and +5.01%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?",
    "url": "https://finnhub.io/api/news?id=1b797f43789f64203f32c818e5119c55c91c7b52c45b338a86430cc800e9d309",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754482502,
      "headline": "Charles River Laboratories (CRL) Q2 Earnings and Revenues Surpass Estimates",
      "id": 136237610,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CRL",
      "source": "Yahoo",
      "summary": "Charles River (CRL) delivered earnings and revenue surprises of +24.80% and +5.01%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?",
      "url": "https://finnhub.io/api/news?id=1b797f43789f64203f32c818e5119c55c91c7b52c45b338a86430cc800e9d309"
    }
  },
  {
    "ts": null,
    "headline": "Charles River raises profit forecast on growing demand for drug development services",
    "summary": "The Wilmington, Massachusetts-based contract drug developer raised its 2025 adjusted profit forecast to $9.90 to $10.30 per share, compared with its previous projection of $9.30 to $9.80.  Contract research organizations, which reported quarterly results over the last month, have all posted better-than-expected profit, reflecting a rebound in spending from pharmaceutical and biotech clients after a cautious stretch driven by tighter sector financing.  \"We are continuing to see clear signs that the biopharmaceutical demand is stabilizing, and in this environment, we are making gradual progress to return to organic revenue growth,\" Charles River CEO James Foster said.",
    "url": "https://finnhub.io/api/news?id=fbe317e351add6183ffacd589fd19e54aee1d6bec690e710aa90af19b7102de2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754481342,
      "headline": "Charles River raises profit forecast on growing demand for drug development services",
      "id": 136232400,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CRL",
      "source": "Yahoo",
      "summary": "The Wilmington, Massachusetts-based contract drug developer raised its 2025 adjusted profit forecast to $9.90 to $10.30 per share, compared with its previous projection of $9.30 to $9.80.  Contract research organizations, which reported quarterly results over the last month, have all posted better-than-expected profit, reflecting a rebound in spending from pharmaceutical and biotech clients after a cautious stretch driven by tighter sector financing.  \"We are continuing to see clear signs that the biopharmaceutical demand is stabilizing, and in this environment, we are making gradual progress to return to organic revenue growth,\" Charles River CEO James Foster said.",
      "url": "https://finnhub.io/api/news?id=fbe317e351add6183ffacd589fd19e54aee1d6bec690e710aa90af19b7102de2"
    }
  },
  {
    "ts": null,
    "headline": "Charles River Laboratories International, Inc. 2025 Q2 - Results - Earnings Call Presentation",
    "summary": "The following slide deck was published by Charles River Laboratories International, Inc.",
    "url": "https://finnhub.io/api/news?id=08edc5275bc2be2e67ff10676bc845b222903d4acbab9c7145c871089aabec57",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754481089,
      "headline": "Charles River Laboratories International, Inc. 2025 Q2 - Results - Earnings Call Presentation",
      "id": 136238373,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "CRL",
      "source": "SeekingAlpha",
      "summary": "The following slide deck was published by Charles River Laboratories International, Inc.",
      "url": "https://finnhub.io/api/news?id=08edc5275bc2be2e67ff10676bc845b222903d4acbab9c7145c871089aabec57"
    }
  },
  {
    "ts": null,
    "headline": "Charles River: Q2 Earnings Snapshot",
    "summary": "On a per-share basis, the Wilmington, Massachusetts-based company said it had profit of $1.06. Earnings, adjusted for one-time gains and costs, came to $3.12 per share. The results exceeded Wall Street expectations.",
    "url": "https://finnhub.io/api/news?id=be10fd3f8db91fd96e1083acf5133d48b98dff944c415ed1971ead5b279a4ed9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754479640,
      "headline": "Charles River: Q2 Earnings Snapshot",
      "id": 136232770,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CRL",
      "source": "Yahoo",
      "summary": "On a per-share basis, the Wilmington, Massachusetts-based company said it had profit of $1.06. Earnings, adjusted for one-time gains and costs, came to $3.12 per share. The results exceeded Wall Street expectations.",
      "url": "https://finnhub.io/api/news?id=be10fd3f8db91fd96e1083acf5133d48b98dff944c415ed1971ead5b279a4ed9"
    }
  },
  {
    "ts": null,
    "headline": "Charles River Laboratories Announces Second-Quarter 2025 Results",
    "summary": "WILMINGTON, Mass., August 06, 2025--Charles River Laboratories Announces Second-Quarter 2025 Results",
    "url": "https://finnhub.io/api/news?id=8301b7a794c1951db95299312a15901c077d8df5f1750c1cb6c9ae3897f46575",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754478000,
      "headline": "Charles River Laboratories Announces Second-Quarter 2025 Results",
      "id": 136232771,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CRL",
      "source": "Yahoo",
      "summary": "WILMINGTON, Mass., August 06, 2025--Charles River Laboratories Announces Second-Quarter 2025 Results",
      "url": "https://finnhub.io/api/news?id=8301b7a794c1951db95299312a15901c077d8df5f1750c1cb6c9ae3897f46575"
    }
  }
]